Neuroscience Letters 426 (2007) 97–100
d-Amino acid oxidase (DAO) genotype and mood
symptomatology in schizophrenia
Aiden Corvin ∗ , Gary Donohoe, Kevin McGhee, Kevin Murphy, Niamh Kenny,
Siobhan Schwaiger, Jeanne Marie Nangle, Derek Morris, Michael Gill
Neuropsychiatric Genetics Group, Institute of Molecular Medicine, Trinity College Dublin, St. James Hospital, James’s Street, Dublin 8, Ireland
Received 27 April 2007; received in revised form 1 August 2007; accepted 5 September 2007
Abstract
A series of genetic studies have identified the d-amino acid oxidase (DAO) gene as potentially contributing to schizophrenia susceptibility.
An interacting gene, d-amino acid oxidase activator (DAOA) has also been implicated and it has been suggested that variation at these genes
may influence the efficiency of glutamate gating at N-methyl-d-aspartate-type (NMDA) receptors. However, recent data suggests that DAOA may
influence susceptibility to mood episodes across the spectrum of psychotic disorders rather than contributing to a specific psychosis phenotype. The
aim of this study was to determine whether risk variation at DAO is similarly associated with affective or other clinical symptoms in psychosis. We
have previously reported association between risk variation at DAO and schizophrenia in an Irish case–control sample. In this study we investigated
the relationship between a defined genetic risk variant at DAO and PANSS-derived clinical symptom factors in a sample of 249 patients using
principal component and Kruskal–Wallis analyses. Carriers of the DAO risk variant scored significantly higher on the ‘depression/anxiety’ factor
than non-carriers (H = 9.02, d.f. = 2, p = 0.01). These data suggest a potential role for DAO in susceptibility to depressive symptoms in schizophrenia,
but a more general role for DAO in affective disorders cannot be excluded.
© 2007 Elsevier Ireland Ltd. All rights reserved.
Keywords: Psychosis; Depression/anxiety; Susceptibility genes; DAO
d-Amino acid oxidase (DAO) is a peroxisomal enzyme
expressed in the human brain, which is known to oxidize dserine and may have a regulatory role in NMDA receptor
function. At least five independent genetic association studies
support the involvement of DAO in schizophrenia susceptibility (reviewed in [4,15]). The original study by Chumakov et
al. identified association with a novel gene (G72/G30); protein interaction between this gene and DAO; and epistasis
between the genes in contributing to schizophrenia risk [1].
The authors proposed that the DAO and G72/G30 (subsequently renamed d-amino acid oxidase activator (DAOA)) genes
contribute to schizophrenia susceptibility by altering the efficiency of glutamate gating at the N-methyl-d-aspartate-type
(NMDA) receptor ion channel. This hypothesis is supported
by evidence that individuals with schizophrenia have reduced
serum levels of d-serine, a decreased ratio of d-serine/DAO
expression and increased DAOA expression [5–7,12]. Thera-
∗
Corresponding author. Tel.: +353 1 608 3272; fax: +353 1 679 8558.
E-mail address: acorvin@tcd.ie (A. Corvin).
0304-3940/$ – see front matter © 2007 Elsevier Ireland Ltd. All rights reserved.
doi:10.1016/j.neulet.2007.09.002
peutic benefits have also been reported in schizophrenia patients
treated with d-serine and other NMDA glycine-binding site
agonists [13].
As molecular genetic data has accrued, there has been speculation that variation at certain genes may contribute to a
mood-psychosis spectrum rather than to discrete categorical
diagnoses such as schizophrenia or bipolar disorder [3]. The
aim of this study was to characterize the clinical effects of variation at the DAO gene. There is strong a priori evidence to
suggest that DAO risk alleles may contribute to the expression of
affective symptoms in schizophrenia and possibly in other disorders. First, DAO have been implicated in genetic susceptibility
to another mood-psychosis spectrum disorder namely bipolar
disorder [3]. Second, DAO is located in a chromosomal region
that has been linked to recurrent depressive disorder in a large
study of almost 500 sibling pairs [8]. Third, studies have reported
association between DAOA/G30 and mood congruent persecutory symptoms in bipolar disorder [9]. Finally, in a recent study
of bipolar disorder and schizophrenia, variation at DAOA/G30
influenced susceptibility to major mood episodes rather than categorical diagnoses [14]. If DAO and DAOA are mood-psychosis
98
A. Corvin et al. / Neuroscience Letters 426 (2007) 97–100
spectrum genes contributing to the same molecular pathway one
would expect that DAO also influences susceptibility to mood
symptoms in psychosis populations.
We have recently identified evidence for association with
DAO in a European case–control sample, most significantly
at marker re3918346 (χ2 = 6.69, p value = 0.01, OR = 1.32
(1.06–1.65)), where the C allele was over-represented in a
sample of 373 schizophrenia cases compared to 812 controls
[2]. Association has also been reported at this marker in three
other published studies of Caucasian schizophrenia populations, although two of the studies report a different direction
of effect [15]. The purpose of the current study was to investigate the relationship between the DAO risk allele in our
sample and clinical symptoms in schizophrenia. We hypothesized that carriers of the DAO risk variant in this population are
likely to have more prominent depressive symptoms than noncarriers.
The study received the approval of the relevant local ethics
committees governing the recruitment centres and was carried out in accordance with the Declaration of Helsinki. The
investigation included 249 ethnically Irish individuals meeting
DSM-IV criteria for schizophrenia (n = 196) or schizoaffective
disorder (n = 59). Cases were recruited, with written informed
consent, primarily through local mental health services in the
Republic of Ireland. Participants were interviewed by a psychiatrist or psychiatric nurse trained to use the Structured Clinical
Interview for DSM (SCID-P) and Positive and Negative Symptom Scale (PANSS) rated on the basis of worst documented
episode of illness. Diagnoses were made by the consensus
lifetime best estimate method using DSM-IV criteria and all
available information (SCID interview, family or staff report
and medical records).
In a previous investigation of DAO we had genotyped four
SNPs across the gene and identified significant evidence of association at the SNP rs3918346. Given this finding and positive
reports from other samples at the SNP, to reduce the number of
tests performed, only this SNP was investigated in the current
study. The SNP rs3918346 was genotyped using the Taqman®
assay (Applied Biosystems, Warrington, UK) on an ABI PRISM
7900HT Sequence Detection System. The genotype frequencies were in Hardy–Weinberg equilibrium for case and control
samples.
The 30 items of the PANSS were submitted to a principal
components analysis (PCA) with varimax rotation implemented
in the program SPSS version 12. Determination of the number
of factors that best accounted for covariance among these items
was based on scree plot analysis and an eigenvalue greater than 1
(this information is available as a Supplementary table). Carriers
and non-carriers of the risk allele were than compared on the
mean score on each factor. Given the unequal n-sizes between
groups, this was carried out using a series of non-parametric
Kruskal–Wallis tests.
Analyses were carried out as a comparison between patients
carrying two copies (n = 159), one copy (n = 79) and 0 copies
(n = 13) of the risk variant (allele C at rs3918346). No differences were observed between carriers and non-carriers on
age, gender, duration of illness, or medication prescribed (typical, atypical or clozapine) (see Table 1). Following principal
components analysis of the PANSS items, five factors emerged
with eigenvalues greater than 1 and accounting for greater than
5% of symptom variance. The factors identified were consistent with results of previous analyses in chronic schizophrenia
or functional psychosis and with clinical expectation. These
factors collectively accounted for 58% of total symptom variance and were characterized as ‘negative’, ‘delusional/thought
disorder’, ‘perceptual/cognitive’, ‘depression/anxiety’ and ‘hostility/impulsivity’ symptom factors.
In a series of Kruskal–Wallis tests for each factor, risk
allele carriers had significantly higher scores for the ‘depression/anxiety’ factor (H = 9.02, d.f. = 2, p = 0.01). In a post hoc
comparison between carriers and non-carriers of individual
PANSS items for this factor, this effect was explained by carriers
Table 1
(A) Comparisons between cases with 0, 1 and 2 risk alleles for demographic variables (χ2 -tests, d.f. = 2) and (B) Kruskal–Wallis analyses of the five factors (H-tests,
d.f. = 2); (**p = 0.01)
Part (A)
Age
Gender (% male)
Duration of illness
Diagnosis (% SZ)
Prescribed atypicals (%)
Prescribed Clozapine (%)
Part (B)
PANSS factors
Delusional/thought disorder
Negative
Perceptual/cognitive
Depression/anxiety
Hostility/impulsivity
2 risk alleles (n = 159)
1 risk allele (n = 79)
0 risk alleles (n = 13)
χ2
44.43 (13.78)
69.2
20.54 (7.8)
74.8
59.7
17.6
43.29 (15.37)
62
19.43 (81.2)
75.9
48.1
22.8
45.62 (13.57)
61.5
21.62 (11.1)
92.3
38.5
15.4
0.31
1.36
0.49
2.52
1.04
4.40
2 risk alleles (n = 159)
1 risk allele (n = 79)
0 risk alleles (n = 13)
H
0.0146 (0.998)
0.0837 (0.964)
0.0858 (0.920)
0.1234 (1.00)
−0.0081(0.997)
0.0739 (−0.180)
−0.1467 (0.170)
−0.0407 (−0.119)
−0.1536 (−0.493)
0.0494 (−0.235)
1.03904 (0.898)
1.04791 (0.847)
1.09568 (0.940)
0.9203 (1.01)
0.9601(1.22)
0.27
2.94
0.22
9.02**
1.25
A. Corvin et al. / Neuroscience Letters 426 (2007) 97–100
of two or one copy of the risk allele having significantly higher
scores on ‘guilt’ (H = 19.2, d.f. = 2, p = 6 × 10−5 ) and ‘anxiety’
(H = 5.9, d.f. = 2, p = 0.05) items (see Table 1).
To our knowledge this is the first study to investigate clinical
correlates of DAO risk variation in schizophrenia. We selected
a single DAO variant (rs3918346) for examination as this had
the largest effect size in our sample and has been reported as
associated with schizophrenia in four independent studies. We
were interested in whether DAO variation contributes to mood
symptoms in schizophrenia. Based on our factor analysis of
PANSS symptoms we observed that the risk variant was associated with higher scores on the depressive factor, in particular
with symptoms of guilt and anxiety. This suggests that DAO
may contribute to depressive symptoms in psychosis. An alternative explanation is that DAO modifies severity of depressive
symptoms, as the measure used in this study reflected an estimate of ‘worst-ever’ PANSS symptoms. These hypotheses can
be plausibly tested using longitudinal measures of clinical symptoms, for example, available through prospective first episode
studies.
In interpreting this data it is important to be clear that the
association with DAO is statistical and that functional risk variants at the gene have yet to be identified. The risk allele identified
is unlikely to represent the causative variant at DAO and may be
in linkage disequilibrium with one or more functional variants
at the locus. The marker investigated here has been associated
with schizophrenia susceptibility in four studies of Caucasian
schizophrenia cohorts (but not in Asian samples), but these studies are evenly divided as to which is the ‘risk’ allele. Potential
reasons for this are manifold and may represent the effect of
allelic heterogeneity, a ‘signal’ from different combinations of
risk variants or false positive reports. Additional association and
sequencing studies are required to explore and characterize risk
variation at the gene as a prelude to identifying how this may
contribute to cellular pathogenesis. We do not report a statistical correction for the number of clinical factors tested because
the factors are not completely independent and there is prior
data for involvement of this locus in mood symptoms. However, the reported finding would meets traditional significance
criteria after conservative Bonferroni correction for the five tests
performed.
There is growing evidence that putative schizophrenia or
psychosis genes may contribute to different aspects of clinical
symptomatology (for review, see [10]). This study contributes
to converging evidence for involvement of DAO (and the interacting gene DAOA) with a cluster of symptoms involving guilt,
anxiety and depression. As previously mentioned DAO maps to
an identified susceptibility locus for recurrent depressive disorder [8]. The DAOA gene has been associated with mood
congruent persecutory delusions in bipolar disorder and mood
episodes across psychotic disorders [9,14]. Beyond the psychosis phenotype there are DAOA associations reported with
susceptibility to panic disorder and major depressive disorder
[10,11]. The current finding, if independently confirmed, suggests that DAO, DAOA and potentially other genes involved in
NMDA function should also be more widely investigated for
association with affective and anxiety disorder phenotypes.
99
Acknowledgements
The authors are grateful to all the participants in this study
and to the support of our funding agencies, namely, The Health
Research Board of Ireland (HRB) and Science Foundation Ireland (SFI).
Appendix A. Supplementary data
Supplementary data associated with this article can be found,
in the online version, at doi:10.1016/j.neulet.2007.09.002.
References
[1] I. Chumakov, M. Blumenfeld, O. Guerassimenko, L. Cavarec, M. Palicio, H. Abderrahim, L. Bougueleret, C. Barry, H. Tanaka, P. La Rosa, A.
Puech, N. Tahri, A. Cohen-Akenine, S. Delabrosse, S. Lissarrague, F.P.
Picard, K. Maurice, L. Essioux, P. Millasseau, P. Grel, V. Debailleul, A.M.
Simon, D. Caterina, I. Dufaure, K. Malekzadeh, M. Belova, J.J. Luan, M.
Bouillot, J.L. Sambucy, G. Primas, M. Saumier, N. Boubkiri, S. Martin
Saumier, M. Nasroune, H. Peixoto, A. Delaye, V. Pinchot, M. Bastucci, S.
Guillou, M. Chevillon, R. Sainz-Fuertes, S. Meguenni, J. Aurich-Costa, D.
Cherif, A. Gimalac, C. Van Duijn, D. Gauvreau, G. Ouellette, I. Fortier,
J. Raelson, T. Sherbatich, N. Riazanskaia, E. Rogaev, P. Raeymaekers, J.
Aerssens, F. Konings, W. Luyten, F. Macciardi, P.C. Sham, R.E. Straub,
D.R. Weinberger, N. Cohen, D. Cohen, Genetic and physiological data
implicating the new human gene G72 and the gene for d-amino acid oxidase
in schizophrenia, Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 13675–13680.
[2] A. Corvin, K.A. McGhee, K. Murphy, G. Donohoe, J.M. Nangle, S.
Schwaiger, N. Kenny, S. Clarke, D. Meagher, J. Quinn, P. Scully, P.
Baldwin, D. Browne, C. Walsh, J.L. Waddington, D.W. Morris, M. Gill,
Evidence for association and epistasis at the DAOA/G30 and d-amino acid
oxidase loci in an Irish schizophrenia sample. Am. J. Med. Genet. (Part
B: Neuropsych. Genet.), 2007. May 10; [Epub ahead of print] PMID:
17492767.
[3] N. Craddock, M.C. O’Donovan, M.J. Owen, Genes for schizophrenia and
bipolar disorder? Implications for psychiatric nosology, Schizophr. Bull.
32 (2006) 9–16.
[4] S.D. Detera-Wadleigh, F.J. McMahon, G72/G30 in schizophrenia and bipolar disorder: review and meta-analysis, Biol. Psychiatry 60 (2006) 106–114.
[5] K. Hashimoto, T. Fukushima, E. Shimizu, N. Komatsu, H. Watanabe, N.
Shinoda, M. Nakazato, Decreased serum levels of d-serine in patients with
schizophrenia: evidence in support of the N-methyl-d-aspartate receptor
hypofunction hypothesis of schizophrenia, Arch. Gen. Psychiatry 60 (2003)
572–576.
[6] K. Hashimoto, G. Engberg, E. Shimizu, C. Nordin, L.H. Lindstrom, M. Iyo,
Reduced d-serine to total serine ratio in the cerebrospinal fluid of drug naı̈ve
schizophrenic patients, Prog. Neuropsychopharmacol. Biol. Psychiatry 29
(2005) 767–769.
[7] M. Korostishevsky, M. Kaganovich, A. Cholostoy, M. Ashkenazi, Y. Ratner, D. Dehary, J. Bernstein, U. Bening-Abu-Shach, E. Ben-Asher, D.
Lancet, M. Ritsner, R. Navon, Is the G72/G30 locus associated with
schizophrenia? Single nucleotide polymorphisms, haplotypes and gene
expression analyses, Biol. Psychiatry 56 (2004) 169–176.
[8] P. McGuffin, J. Knight, G. Breen, S. Brewster, P.R. Boyd, N. Craddock, M.
Gill, A. Korszun, W. Maier, L. Middleton, O. Mors, M.J. Owen, J. Perry, M.
Prisig, T. Reich, J. Rice, M. Rietschel, L. Jones, P. Sham, A. Farmer, Whole
genome linkage scan of recurrent depressive disorder from the depression
network study, Hum. Mol. Genet. 14 (2005) 3337–3345.
[9] T.G. Schulze, S. Ohlraun, P.M. Czerski, J. Schumacher, L. Kassem, M.
Deschner, M. Gross, M. Tullius, V. Heidmann, S. Kovalenko, R. Abou
Jamra, T. Becker, A. Leszczynska-Rodziewicz, T. Illig, N. Klopp, S.
Wellek, S. Cichon, F.A. Henn, F.J. McMahon, W. Maier, P. Propping, M.
Nothen, M. Rietschel, Genotype-phenotype studies in Bipolar Disorder
showing association between the DAOA/G30 locus and persecutory delu-
100
A. Corvin et al. / Neuroscience Letters 426 (2007) 97–100
sions: a first step towards a molecular genetic classification of psychiatric
phenotypes, Am. J. Psychiatry (2005) 2101–2108.
[10] J. Schumacher, R. Abou Jamra, T. Becker, N. Klopp, P. Franke, C. Jacob, P.
Sand, J. Fritze, S. Ohlraun, T.G. Schulze, M. Rietschel, T. Illig, P. Propping,
S. Cichon, J. Deckert, M.M. Nothen, Investigation of the DAOA/G30 locus
in panic disorder, Mol. Psychiatry 10 (2005) 428–429.
[11] J. Schumacher, R.A. Jamra, J. Freudenberg, T. Becker, S. Ohlraun, A.C.
Otte, M. Tullius, S. Kovalenko, A.V. Bogaert, W. Maier, M. Rietschel,
P. Propping, M.M. Nothen, S. Cichon, Examination of G72 and d-amino
acid oxidase as genetic risk factors for schizophrenia and bipolar affective
disorder, Mol. Psychiatry 9 (2004) 203–207.
[12] C.T. Toro, P.R. Kasher, J.F.W. Deakin, Altered d-serine metabolism in
schizophrenia? A post-mortem study using the Stanley Consortium brains,
Schizophr. Res. (2004) 125S–126S.
[13] H.J. Tuominen, J. Tiihonen, K. Wahlbeck, Glutamatergic drugs for
schizophrenia Cochrane Database Systems Reviews, 2006, CD003730.
[14] N.M. Williams, E.K. Green, S. MacGregor, S. Dwyer, N. Norton, H.
Williams, R. Raybold, D. Grozeva, M. Hamshere, S. Zammit, L. Jones,
A. Cardno, G. Kirov, I. Jones, M.C. O’Donovan, M.J. Owen, N. Craddock,
Variation at the DAOA/G30 locus influences susceptibility to major mood
episodes but not psychosis in schizophrenia and bipolar disorder, Arch.
Gen. Psychiatry 63 (2006) 366–373.
[15] L.S. Wood, E.H. Pickering, B.M. Decairo, Significant support for DAO
as a schizophrenia susceptibility locus: examination of five genes putatively associated with schizophrenia, Biol. Psychiatry 61 (2007) 1195–
1199.
All in-text references underlined in blue are linked to publications on ResearchGate, letting you access and read them immediately.